CN108314708A - 一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用 - Google Patents
一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用 Download PDFInfo
- Publication number
- CN108314708A CN108314708A CN201710030851.4A CN201710030851A CN108314708A CN 108314708 A CN108314708 A CN 108314708A CN 201710030851 A CN201710030851 A CN 201710030851A CN 108314708 A CN108314708 A CN 108314708A
- Authority
- CN
- China
- Prior art keywords
- farbricius
- bursa
- vaccine
- immune
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001260012 Bursa Species 0.000 title claims abstract description 29
- 229960005486 vaccine Drugs 0.000 title abstract description 39
- 230000000694 effects Effects 0.000 title abstract description 20
- 230000036039 immunity Effects 0.000 title abstract description 13
- 238000006243 chemical reaction Methods 0.000 title abstract description 6
- 230000001737 promoting effect Effects 0.000 title abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 25
- 229920001184 polypeptide Polymers 0.000 claims abstract description 22
- 206010014599 encephalitis Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 244000144977 poultry Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 108091064702 1 family Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 8
- 210000004698 lymphocyte Anatomy 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000000427 antigen Substances 0.000 abstract description 4
- 102000036639 antigens Human genes 0.000 abstract description 4
- 108091007433 antigens Proteins 0.000 abstract description 4
- 230000028993 immune response Effects 0.000 abstract description 4
- HPJLZFTUUJKWAJ-JHEQGTHGSA-N Glu-Gly-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HPJLZFTUUJKWAJ-JHEQGTHGSA-N 0.000 abstract description 3
- AYPMIIKUMNADSU-IHRRRGAJSA-N Phe-Arg-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O AYPMIIKUMNADSU-IHRRRGAJSA-N 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 abstract description 3
- 230000000091 immunopotentiator Effects 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000003616 anti-epidemic effect Effects 0.000 abstract description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 239000012646 vaccine adjuvant Substances 0.000 abstract description 2
- 229940124931 vaccine adjuvant Drugs 0.000 abstract description 2
- JVTYXRRFZCEPPK-RHYQMDGZSA-N Leu-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)N)O JVTYXRRFZCEPPK-RHYQMDGZSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 229940031551 inactivated vaccine Drugs 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- DIBAKBGYJUCGDL-UHFFFAOYSA-N 2,6-diamino-n-[1-[(2-amino-2-oxoethyl)amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]hexanamide Chemical compound NCCCCC(N)C(=O)NC(C(=O)NCC(N)=O)CC1=CN=CN1 DIBAKBGYJUCGDL-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 208000003773 Meningism Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 108010026970 bursopoietin Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003526 lymphopoietic effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 208000023158 meningismus Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种具有促进疫苗免疫反应的法氏囊活性九肽。本发明所述的免疫活性肽是一种来源于法氏囊的小分子多肽,氨基酸组成为Leu Met Thr Phe Arg Asn Glu Gly Thr,结构简单,免疫原性极弱。本发明活性肽具有促进疫苗免疫反应的功能,对小鼠具有刺激抗体产生、细胞免疫反应、淋巴细胞活力增强和提高疫苗免疫效力作用。本发明可作为疫苗佐剂或免疫增强剂应用于动物疫苗应用研究,以提高动物机体针对特异抗原的免疫应答能力,提高疫苗的免疫效力,从而提高动物机体抗疫病感染的能力,可应用于基础免疫研究、临床应用研究等领域。
Description
技术领域
本发明属于兽医生物制品技术领域,具体涉及一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用。
背景技术
日本乙型脑炎(Japaneses encephalitis,简称乙脑)是由乙型脑炎病毒(Japanneses encephalitis virus, JEV)引起的一种危害严重的人畜共患传染病,临床上以高热、意识障碍、抽搐及脑膜刺激症为特征,严重者出现中枢性呼吸衰竭。乙脑病死率高,即使治愈也常伴有后遗症。乙脑病毒的传播主要呈现:猪-蚊-人模式,猪是重要的病毒扩增宿主,人是终末宿主,而蚊子是关键的传播媒介。目前控制乙脑的主要手段是宿主接种疫苗。随着全球气候变暖和人口流动性增大引起的蚊媒传染病发病率上升,JEV的防控策略显得越来越紧迫。因此如何诱导机体产生有效持久的免疫保护应答是相关科研工作人员迫切需要解决的现实问题。
疫苗免疫不仅是当前畜禽传染病防制的主要措施。临床上使用的大多数疫苗配合佐剂才能发挥良好的功效。因而,安全、无残留、有效的新型免疫增强剂研究及技术创新已成为我国动物疫病防控规划的重要举措。
发明内容
本发明的目的在于提供一种价格低、安全、无残留的高效促进疫苗免疫效果的新型活性肽,可作为疫苗佐剂或免疫增强剂应用于动物疫苗应用研究,以提高动物机体针对特异抗原的免疫应答能力,提高疫苗的免疫效力,从而提高动物机体抗疫病感染的能力,可应用于基础免疫研究、临床应用研究等领域。
一种法氏囊多肽BP9,其氨基酸序列如SEQ ID No.1所示,为:5’- Leu Met ThrPhe Arg Asn Glu Gly Thr -3’。
本发明所述法氏囊多肽BP9在制备免疫药物中的应用,优选的在制备畜禽免疫药物中的应用,特别优选的,在制备预防乙型脑炎药物中的应用。
一种预防乙型脑炎的免疫组合物,包含乙型脑炎及所述的法氏囊多肽BP9。
所述法氏囊多肽BP9优选以2~255ug/mL计量存在于免疫组合物中,更优选10~250ug/mL,进一步优选10~50ug/mL,最优选为10ug/mL。
本发明通过超滤浓缩技术,回收分子量1000Da以下的有效成分(即粗提物)。经真空干燥,再次浓缩,溶解后,用反向高效液相色谱(RP-HPLC)分离、纯化多种法氏囊中的活性成分。经MODIL-TOF质谱分析,测定该法氏囊活性肽的分子量为1068.22(m/z),并获得完整的氨基酸序列,即LMTFRNEGT(即 5’- Leu Met Thr Phe Arg Asn Glu Gly Thr - 3’,序列1),并命名为法氏囊多肽(BP9)。在小鼠免疫中,添加0.01mg/mL和0.05mg/mL剂量BP9的实验组JEV疫苗免疫效力显著高于未加该组分的疫苗对照组。
1.法氏囊多肽BP9的制备
利用超滤浓缩和分子筛技术,回收分子量小于1KDa的法氏囊粗提物,经真空冷冻干燥,超纯水稀释后用反向高效液相色谱(RP-HPLC)分离,收获特定洗脱峰值的法氏囊多肽成分。通过刺激杂交瘤细胞,能够抗体水平升高的组分经MODIL-TOF质谱分析,测定该法氏囊活性肽的分子量为1068.22(m/z),并获得该法氏囊多肽的完整氨基酸序列,即LMTFRNEGT。通过人工合成BP9,以一定浓度进行验证实验。
2.法氏囊多肽BP9促进JEV灭活疫苗实验
(1)将免疫活性肽BP9按照10、50和250ug/mL三种剂量添加至JEV灭活疫苗中进行联合接种小鼠;免疫后的小鼠的抗体水平、抗体亚型、中和抗体水平高于疫苗组,且T细胞亚型和淋巴细胞增殖活力发生了变化。
本发明的积极意义:
本发明从法氏囊中分离、鉴定出一个新的免疫活性肽BP9,结构简单,免疫原性极弱,可作为畜禽疫苗免疫增强剂,如促进JEV灭活疫苗的免疫活性。本发明所述的活性肽是一种来源于法氏囊的小分子多肽,安全、无残留、副作用小、具有促进广泛的免疫增强作用,对多种畜禽具有刺激抗体生成、调节细胞因子和提高疫苗免疫效力作用,该多肽的氨基酸序列为:5’-LMTFRNEGT - 3’。
附图说明
图1 法氏囊九肽的分离和纯化。反向高效液相色谱图中,箭头所指,BP9的洗脱峰11.19 min。
图2:MALDI-TOF-MS分析。
图3:免疫后6周,小鼠JEV特异抗体水平,用不同字母标记的各组之间差异显著 (p<0.05),NS代表无显著性差异。
图4:免疫后6周,小鼠JEV特异亚型IgG1和IgG2a抗体水平,用不同字母标记的各组之间差异显著 (p<0.05),NS代表无显著性差异。
图5:二免后1周,小鼠JEV中和抗体水平,用不同字母标记的各组之间差异显著 (p<0.05),NS代表无显著性差异。
图6:二免后1周,小鼠T淋巴细胞亚型CD3+CD4+, CD3+CD8+比例,用不同字母标记的各组之间差异显著 (p<0.05),NS代表无显著性差异。
图7:二免后1周,小鼠淋巴细胞活力,用不同字母标记的各组之间差异显著 (p<0.05),NS代表无显著性差异。
具体实施方式
本发明的实施例为进一步描述本发明的技术方案,但不构成对本发明的限制。
实施例 1
1. BP9的分离及鉴定
取健康4~6周龄鸡的法氏囊(AA肉鸡,上海农业科学院附属养殖场)500克,用1000ml生理盐水碾碎,反复冻融三次,14,000g低温离心60分钟。上清经1000Da分子筛超滤、冻干。超纯水稀释后,0.22um滤膜过滤,经反向高效液相纯化分析,收获洗脱峰值时间为11.19 min的活性峰(见图1),经 MALDI-TOF-MS分析,分子量为1068.22,氨基酸序列LMTFRNEGT(见图2)。
实施例2
1. 人工合成 BP9
委托商业化多肽合成公司按照LMTFRNEGT序列(SEQ ID No.1)合成多肽,要求纯度≧97%。
2. 疫苗
猪用JEV灭活疫苗(购自山东滨州沃华生物工程有限公司)
3. 实验动物分组
将75只BALB/C小鼠随机分为五组,每组15只:(I)PBS 对照组(每只免疫 0.2ml PBS);(II)JEV灭活疫苗免疫组(每只免疫灭活疫苗0.2ml);(III~V)灭活疫苗 +BP9 组(BP9浓度分别为10、50、250ug/mL,免疫剂量均为0.2ml);采用腹腔注射的方式对相应组小鼠分别进行两次免疫。免疫间隔两周,200ul/每只/每次(表1)。
4. 样品采集
小鼠二免后,每周眼眶采血,8000×g离心10min分离血清,测定抗体水平和抗体亚型水平;并于第二次免疫后1周采血分离血清,采用蚀斑减少法测定中和抗体,采用流式细胞术检测了第二次免疫后一周小鼠血液中淋巴细胞及其亚群的情况,所有检测结果进行统计分析。
表 1 小鼠免疫程序
0 天 | 14天 | |
Ⅰ | PBS | PBS |
Ⅱ | JEV疫苗(vaccine) | JEV疫苗(vaccine) |
Ⅲ | 0.01mg/ml BP9+ JEV疫苗 | 0.01mg/ml BP9+ JEV疫苗 |
Ⅳ | 0.05mg/ml BP9+ JEV疫苗 | 0.05mg/ml BP9+ JEV疫苗 |
Ⅴ | 0.25mg/ml BP9+ JEV疫苗 | 0.25mg/ml BP9+ JEV疫苗 |
5. 结果
(1)抗体水平检测结果
采用间接ELISA方法测定了小鼠免疫后6周的血清中针对JEV抗原的抗体水平,结果见图3。实验显示,第六周,BP9联合免疫组与只免疫疫苗组小鼠相比,抗体水平出现极显著差异,且灭活疫苗+0.01mg/ml BP9组的抗体水平最高。
(2)抗体亚型水平检测结果
免疫后6周采血分离血清,用ELISA方法对各组小鼠血清中JEV特异的抗体亚型检测检测,结果见图4。结果表明,与疫苗组对照相比,BP9联合免疫组明显提高IgG1和IgG2a抗体水平,不过随着BP9浓度的增加,而两种抗体亚型水平则下降,这说明BP9促进疫苗免疫的能力与其剂量密切相关。
(3)中和抗体水平检测结果
采用蚀斑形成与蚀斑减少实验测定小鼠二免后一周的血清中针对JEV的中和抗体的水平,结果见图5。BP9对中和抗体的产生有明显的剂量依赖性,免疫剂量为0.01mg/ml时,促进效果最明显(与单独免疫抗原的组相比,差异极显著,P<0.0001)且剂量越大,对抗体产生的促进效果越小,0.25mg/ml剂量时,基本无促进效果。
(4)T细胞亚型结果
采用PE、FITC和PE-Cy5标记的CD3、CD4和CD8 单抗 (eBioscience,USA)三色的流式细胞术技术检测了第二次免疫后一周小鼠血液中淋巴细胞及其亚群的情况,结果见图6。结果实验表明,与PBS组相比,免疫了JEV疫苗的小鼠CD4+ T细胞(CD3+CD4+)所占百分比下降,而CD8+ T细胞(CD3 +CD8+)占比上升。BP9联合JEV疫苗组与疫苗对照组相比,基本无变化,仅有0.01mg/ml组的CD4+ T细胞占比显著下降。
(5)淋巴细胞增殖结果
采用了MTT比色法检测了BP9对淋巴细胞增殖的影响情况,B-/T- 淋巴细胞有丝分裂原细菌脂多糖(LPS)/植物血凝素(PHA)作为阳性对照,结果见图7。结果实验表明,与JEV疫苗组相比较,同时BP9联合JEV疫苗组的淋巴细胞增殖能力显著增强,尤其0.01mg/ml BP9的免疫组,细胞增殖情况差异达到极显著水平。此外,与单独的LPS组相比,BP9也显著增强了LPS(10 μg/ml)诱导的脾淋巴细胞的增殖,但有一定浓度依赖性,在0.01 mg/ml的情况下增强效果极显著。与单独的PHA 组相比,BP9显著增强了PHA (10 μg/ml)诱导的脾淋巴细胞的增殖,且0.01mg/ml的增强效果极显著。结果表明,BP9可以作为免疫佐剂强烈刺激免疫反应。
序列表
<110> 南京农业大学
<120> 一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用
<130> 2017
<160> 1
<170> Patent In version 3.5
<210> 1
<211> 9
<212> PRT
<213> 人工合成序列
<400> 1
Leu Met Thr Phe Arg Asn Glu Gly Thr
5
Claims (9)
1.一种法氏囊多肽BP9,其氨基酸序列如SEQ ID No.1所示。
2.权利要求1所述法氏囊多肽BP9在制备免疫药物中的应用。
3.权利要求1所述法氏囊多肽BP9在制备畜禽免疫药物中的应用。
4.权利要求1所述法氏囊多肽BP9在制备预防乙型脑炎药物中的应用。
5.一种预防乙型脑炎的免疫组合物,其特征在于,包含乙型脑炎及权利要求1所述的法氏囊多肽BP9。
6.根据权利要求5所述的免疫组合物,其特征在于,所述法氏囊多肽BP9以2~255ug/mL计量存在于免疫组合物中。
7.根据权利要求6所述的免疫组合物,其特征在于,所述法氏囊多肽BP9以10~250ug/mL计量存在于免疫组合物中。
8.根据权利要求7所述的免疫组合物,其特征在于,所述法氏囊多肽BP9以10~50ug/mL计量存在于免疫组合物中。
9.根据权利要求8所述的免疫组合物,其特征在于,所述法氏囊多肽BP9以10 ug/mL计量存在于免疫组合物中。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710030851.4A CN108314708B (zh) | 2017-01-17 | 2017-01-17 | 一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710030851.4A CN108314708B (zh) | 2017-01-17 | 2017-01-17 | 一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108314708A true CN108314708A (zh) | 2018-07-24 |
CN108314708B CN108314708B (zh) | 2021-03-05 |
Family
ID=62891169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710030851.4A Expired - Fee Related CN108314708B (zh) | 2017-01-17 | 2017-01-17 | 一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108314708B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109180784A (zh) * | 2018-10-31 | 2019-01-11 | 南京农业大学 | 一种促进禽流感和/或新城疫疫苗的免疫反应的法氏囊活性六肽及应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003066833A2 (en) * | 2002-02-08 | 2003-08-14 | New York University | Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies |
WO2004084938A1 (en) * | 2003-03-24 | 2004-10-07 | Intercell Ag | Improved vaccines |
CN1910276A (zh) * | 2004-01-21 | 2007-02-07 | 康斯乔最高科学研究公司 | 传染性法氏囊病病毒(ibdv)的嵌合空衣壳及其获得方法和应用 |
CN101057971A (zh) * | 2006-04-20 | 2007-10-24 | 河南农业大学 | 一种用于防治畜禽病毒性传染病的药物 |
WO2009024534A2 (en) * | 2007-08-17 | 2009-02-26 | Intercell Ag | Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses |
CN103467571A (zh) * | 2013-09-11 | 2013-12-25 | 江苏农牧科技职业学院 | 一种畜禽免疫增强剂法氏囊多肽 |
CN104829690A (zh) * | 2015-05-06 | 2015-08-12 | 青岛农业大学 | 一种具有促进免疫功能的法氏囊十一肽 |
-
2017
- 2017-01-17 CN CN201710030851.4A patent/CN108314708B/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003066833A2 (en) * | 2002-02-08 | 2003-08-14 | New York University | Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies |
WO2004084938A1 (en) * | 2003-03-24 | 2004-10-07 | Intercell Ag | Improved vaccines |
CN1910276A (zh) * | 2004-01-21 | 2007-02-07 | 康斯乔最高科学研究公司 | 传染性法氏囊病病毒(ibdv)的嵌合空衣壳及其获得方法和应用 |
CN101057971A (zh) * | 2006-04-20 | 2007-10-24 | 河南农业大学 | 一种用于防治畜禽病毒性传染病的药物 |
WO2009024534A2 (en) * | 2007-08-17 | 2009-02-26 | Intercell Ag | Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses |
CN103467571A (zh) * | 2013-09-11 | 2013-12-25 | 江苏农牧科技职业学院 | 一种畜禽免疫增强剂法氏囊多肽 |
CN104829690A (zh) * | 2015-05-06 | 2015-08-12 | 青岛农业大学 | 一种具有促进免疫功能的法氏囊十一肽 |
Non-Patent Citations (3)
Title |
---|
XIAO-DONGLIU等: "Comparison of immunomodulatory functions of three peptides from the chicken bursa of Fabricius", 《REGULATORY PEPTIDES》 * |
王臣等: "《重组法氏囊免疫融合肽的免疫佐剂特性》", 30 November 2016, 中国原子能出版社 * |
王臣等: "胸腺五肽和法氏囊活性五肽的融合表达及其对禽流感灭活疫苗的佐剂效应", 《生物工程学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109180784A (zh) * | 2018-10-31 | 2019-01-11 | 南京农业大学 | 一种促进禽流感和/或新城疫疫苗的免疫反应的法氏囊活性六肽及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108314708B (zh) | 2021-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101830968B (zh) | 一种具有免疫调节作用的法氏囊七肽 | |
CN109134613B (zh) | 一种促进疫苗免疫反应的法氏囊七肽及其应用 | |
CA2922467A1 (en) | Oncology vaccine | |
CN101434650A (zh) | 法氏囊五肽、其衍生肽及其应用 | |
US20230143215A1 (en) | Immunization against sars-cov-related diseases | |
Wu et al. | Glycyrrhiza polysaccharides can improve and prolong the response of chickens to the Newcastle disease vaccine | |
Feng et al. | Isolation and potential immunological characterization of TPSGLVY, a novel bursal septpeptide isolated from the bursa of Fabricius | |
CN107098984A (zh) | 牛膝粗多糖、多糖组分和均一多糖、其制备方法及其用途 | |
Wang et al. | Bursin-like peptide (BLP) enhances H9N2 influenza vaccine induced humoral and cell mediated immune responses | |
CN104402971A (zh) | 一种具有免疫调节作用的多肽 | |
JPH10511088A (ja) | 免疫調節活性を有するペプチド | |
CN110066342A (zh) | 一种具有免疫调节、中和消解内毒素和抗炎功能的杂合肽及其制备方法与应用 | |
CN108314708A (zh) | 一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用 | |
CN106317216B (zh) | 一种促进h9n2禽流感疫苗免疫效果的活性肽及应用 | |
CN109180784B (zh) | 一种促进禽流感和/或新城疫疫苗的免疫反应的法氏囊活性六肽及应用 | |
CN109705194B (zh) | 一种促进aiv和/或ndv疫苗的免疫反应的法氏囊活性五肽及应用 | |
WO2023060483A1 (zh) | 多肽-rbd免疫偶联物及其用途 | |
AU2019262609A1 (en) | Artificial promiscuous T helper cell epitopes that facilitate targeted antibody production with limited T cell inflammatory response | |
CN102724998A (zh) | 用于引发特异性免疫应答以治疗病毒感染和其他病症的具有肽佐剂的疫苗 | |
CN113278634B (zh) | 一种预防和治疗默克尔细胞癌的新型疫苗 | |
Paul et al. | Immunological evaluation of fusion protein of Brugia malayi abundant larval protein transcript-2 (BmALT-2) and Tuftsin in experimental mice model | |
CN105175551B (zh) | 一种抗伪狂犬病毒合成肽疫苗及其用途 | |
CN105175550B (zh) | 一种抗猪圆环病毒合成肽疫苗及其用途 | |
CN105727278B (zh) | 一种羊口疮重组蛋白抗原疫苗及其制备方法 | |
CN112409454B (zh) | 一种法氏囊七肽及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210305 |
|
CF01 | Termination of patent right due to non-payment of annual fee |